American Century Companies Inc. Has $26.85 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ

American Century Companies Inc. grew its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 34.5% in the 2nd quarter, Holdings Channel reports. The fund owned 253,030 shares of the specialty pharmaceutical company’s stock after buying an additional 64,968 shares during the period. American Century Companies Inc.’s holdings in Jazz Pharmaceuticals were worth $26,852,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Rhumbline Advisers boosted its stake in shares of Jazz Pharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 165,012 shares of the specialty pharmaceutical company’s stock valued at $17,511,000 after purchasing an additional 456 shares in the last quarter. Legal & General Group Plc increased its position in Jazz Pharmaceuticals by 11.2% during the 2nd quarter. Legal & General Group Plc now owns 185,824 shares of the specialty pharmaceutical company’s stock worth $19,720,000 after purchasing an additional 18,675 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Jazz Pharmaceuticals by 3.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company’s stock valued at $182,664,000 after purchasing an additional 59,252 shares during the last quarter. Ensign Peak Advisors Inc boosted its position in Jazz Pharmaceuticals by 17.9% in the second quarter. Ensign Peak Advisors Inc now owns 28,435 shares of the specialty pharmaceutical company’s stock valued at $3,018,000 after buying an additional 4,316 shares in the last quarter. Finally, EMC Capital Management acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $344,000. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 3,415 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $177.78, for a total transaction of $607,118.70. Following the completion of the transaction, the director owned 20,449 shares in the company, valued at approximately $3,635,423.22. This trade represents a 14.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce C. Cozadd sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $181.09, for a total transaction of $3,259,620.00. Following the completion of the transaction, the director owned 390,826 shares in the company, valued at $70,774,680.34. This trade represents a 4.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,893 shares of company stock valued at $8,559,699 over the last ninety days. Insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JAZZ. UBS Group reiterated a “neutral” rating and set a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. The Goldman Sachs Group boosted their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Truist Financial upped their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Wells Fargo & Company increased their target price on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Thirteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $195.67.

Jazz Pharmaceuticals Stock Down 0.2%

Shares of JAZZ opened at $176.61 on Monday. The stock’s 50-day moving average price is $143.87 and its two-hundred day moving average price is $125.27. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $182.99. The company has a market capitalization of $10.73 billion, a PE ratio of -26.24, a PEG ratio of 8.49 and a beta of 0.29. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.